Poluektov Yuri M, Lopina Olga D, Strelkova Maria A, Kuleshova Iuliia D, Makarov Alexander A, Petrushanko Irina Yu
Engelhardt Institute of Molecular Biology Russian Academy of Sciences, Moscow, Russia.
Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia.
Front Pharmacol. 2025 Mar 24;16:1520927. doi: 10.3389/fphar.2025.1520927. eCollection 2025.
Cardiotonic steroids (CTSs) were known as steroidal plant compounds that exert cellular effects by the binding to Na,K-ATPase. Earlier, plant (exogenous) CTSs were used to treat chronic heart failure. By now, endogenous CTS have been identified in mammals, and their concentrations in the blood, normally in a subnanomolar range, are altered in numerous pathologies. This indicates their role as endogenous regulators of physiological processes. CTS transport occurs primarily in the blood, yet the CTS effects on blood cells remain poorly understood. This review summarizes the CTS effects on blood cells of animals and humans under normal and pathological conditions, and analyzes their action based on known mechanisms of action in mammalian cells. At high concentrations (greater than 10 M), CTS binding to Na,K-ATPase inhibits the enzyme, whereas lower concentrations of CTSs induce signaling cascades or activate the enzyme. All these mechanisms are shown to be present in blood cells. The particular CTS effect is determined by the CTS type, its concentration, the isoform composition of the catalytic α-subunit of Na,K-ATPase in the cell, and other cell features. It has been demonstrated that all blood cell types (erythrocytes, leukocytes, and platelets) expressed both ubiquitously distributed α1-isoform and tissue-specific α3-subunit, which exhibits a different ion and CTS affinity compared to α1. This results in a wide spectrum of blood cell responses to fluctuations in CTS levels in the blood. In particular, an increase in the level of endogenous CTSs by a more twofold is sufficient to induce a decline in the activity of erythrocyte Na,K-ATPase. The administration of exogenous CTSs is able to modulate the proinflammatory activity of leukocytes, which is attributed to the activation of signaling cascades, and to exert an influence on platelet activation. Hence, alterations of CTS levels in bloodstream significantly affect the functionality of blood cells, contributing to the organism's adaptive response. On top of this, a comparison of the effects of CTSs on human leukocytes and rodent leukocytes carrying the CTS-resistant α1-isoform often reveals opposite effects, thus indicating that rodents are an unsuitable model for studying CTS effects on these cells.
强心甾体(CTS)是一类甾体类植物化合物,通过与钠钾-ATP酶结合发挥细胞效应。早期,植物源性(外源性)CTS被用于治疗慢性心力衰竭。目前,已在哺乳动物体内鉴定出内源性CTS,其在血液中的浓度通常处于亚纳摩尔范围内,并且在多种病理状态下会发生改变。这表明它们作为生理过程的内源性调节因子发挥作用。CTS主要在血液中运输,但其对血细胞的影响仍知之甚少。本综述总结了正常和病理条件下CTS对动物和人类血细胞的影响,并基于已知的在哺乳动物细胞中的作用机制分析了它们的作用。在高浓度(大于10 μM)时,CTS与钠钾-ATP酶结合会抑制该酶,而较低浓度的CTS会诱导信号级联反应或激活该酶。所有这些机制在血细胞中均有体现。特定的CTS效应取决于CTS的类型、其浓度、细胞中钠钾-ATP酶催化α亚基的同工型组成以及其他细胞特征。已证明所有血细胞类型(红细胞、白细胞和血小板)均表达普遍分布的α1同工型和组织特异性的α3亚基,与α1相比,α3表现出不同的离子和CTS亲和力。这导致血细胞对血液中CTS水平波动产生广泛的反应。特别是,内源性CTS水平升高两倍以上足以导致红细胞钠钾-ATP酶活性下降。外源性CTS的给药能够调节白细胞的促炎活性,这归因于信号级联反应的激活,并对血小板活化产生影响。因此,血液中CTS水平的改变会显著影响血细胞的功能,有助于机体的适应性反应。除此之外,比较CTS对携带CTS抗性α1同工型的人类白细胞和啮齿动物白细胞的影响时,常常会发现相反的效应,这表明啮齿动物不是研究CTS对这些细胞影响的合适模型。